News

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.
Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.
Regeneron Pharmaceuticals (NASDAQ:REGN) saw its stock increase by 2.8% after the U.S. Food and Drug Administration granted ...
Investing.com -- Regeneron Pharmaceuticals (NASDAQ: REGN) stock rose 2.8% after the U.S. Food and Drug Administration granted accelerated approval for the company’s blood cancer therapy Lynozyfic.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...
Allspring Global Investments Holdings LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report ...
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was downgraded by stock analysts at Argus from a “buy” rating to a ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday after Wells Fargo & Company raised their price target on the stock from ...
Regeneron Pharmaceuticals REGN +2.83% Get Free Report has outperformed the market over the past 20 years by 13.87% on an annualized basis producing an average annual return of 22.35%. Currently, ...
Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...
Sequoia Financial Advisors LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.7% in ...